Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B

Next Previous
Trial Profile

Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABX 203 (Primary) ; ABX 203 (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Sponsors Abivax

    • Most Recent Events

    • 26 Jun 2022 Results assessing association of relapse after nucleotide analogue cessation with baseline serum HBV-RNA level in a large cohort of HBeAg negative patients from ABX-203 trial or in an observational register trial (Terminator 2) presented at The International Liver Congress 2022
    • 26 Jun 2021 Results (n=136) assessing association of serum anti-HBc with relapse after stop of nucleoside/nucleotide analogue therapy in HBeAg negative patients presented at The International Liver Congress 2021
    • 29 Aug 2020 Results assessing use of soluble immune markers (SIMs) in predicting virological relapse, presented at The International Liver Congress 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top